Ricoh Exits 3D Printed Medical Devices With Myrava Sale

A brief healthcare experiment ends

Ricoh USA sold its Ricoh 3D for Healthcare business to Myrava, a medical device company focused on personalized, point-of-care manufacturing. The deal, announced July 6, covers the patient-specific implant and surgical model operations Ricoh launched in 2025. Terms were not disclosed.

Bob Lamendola, Chief Digital Services and Delivery Officer at Ricoh USA, said the sale reflects the company's decision to concentrate on process automation, workplace technology, and business services. "While healthcare remains a key growth area for Ricoh, patient-specific medical devices require specialized capabilities that extend beyond the scope of our broader business priorities," he said.

Myrava inherits an established operation

Gary Turner, now CEO of Myrava, previously ran Ricoh 3D for Healthcare as its Vice President and General Manager. That continuity should make the transition smoother for customers and clinical partners. Myrava says it will keep the existing operations intact and invest in expanding FDA-cleared, patient-specific manufacturing capabilities.

The Ricoh 3D for Healthcare unit produced custom surgical guides, anatomical models, and patient-specific implants used in pre-surgical planning. Myrava plans to maintain those services while adding dedicated investment in regulatory expansion and point-of-care manufacturing for hospitals.

What the sale signals about medical 3D printing

Ricoh's exit does not mean the medical 3D printing market is shrinking. If anything, it is the opposite: the technology is becoming specific enough that large diversified companies with broad portfolios are choosing to leave specialized production to focused operators. Myrava buying a turnkey operation rather than building one from scratch suggests there is real value in the existing infrastructure and FDA clearance work Ricoh accumulated.

For hospitals and surgeons who relied on Ricoh 3D for Healthcare for patient-specific models and guides, the transition to Myrava should be transparent. The same facility and team are staying in place, just under new ownership with a narrower, more specialized mandate.